Agena Bioscience Introduces the Hemo ID™ Panel for Blood Group Genotyping at the 33rd International Congress of the ISBT in S

 Agena Bioscience Introduces the Hemo ID™ Panel for Blood Group Genotyping at
         the 33rd International Congress of the ISBT in Seoul, Korea

Swiss Red Cross Study Recommends Replacing Kell, Kidd, Duffy Serotyping with
Genotyping

PR Newswire

SAN DIEGO, June 4, 2014

SAN DIEGO, June 4, 2014 /PRNewswire/ -- Agena Bioscience, Inc., which recently
acquired the Bioscience business of Sequenom, Inc., today, introduced the Hemo
ID^™ Blood Group Genotyping Panel for the MassARRAY^® System following a Swiss
Red Cross study using a beta version of the panel published in the journal
Transfusion. The study, which genotyped and serotyped more than 4,000 blood
donors for the Kell, Kidd, and Duffy blood group systems, observed a
concordance of more than 99% between serotyping and genotyping. Discrepancies
were primarily a result of erroneous serologic profiles or, in three cases,
newly observed silencing alleles.

Agena Bioscience is a San Diego, CA based life sciences and clinical
diagnostics company that offers the MassARRAY System. The system is a highly
sensitive, quantitative method for nucleic acid detection via MALDI-TOF mass
spectrometry for high-throughput genotyping and mutation profiling for cancer
and other disease research, companion diagnostics, pharmacogenomics,
epigenetics, clinical genetics, ag-bio, genetics, and biobanking molecular
sample identification.

The study's authors concluded that "serotyping should be replaced by
genotyping for donors' blood groups encoded by KEL, SLC14A1, and DARC," based
on consideration of Agena Bioscience's MassARRAY genotyping technology's
specificity, throughput, quality, and cost. Although a full cost-effectiveness
study was not conducted, MassARRAY based genotyping was found to be
"comparable to, or even lower in cost than, conventional serology."

"Preventing potentially fatal alloimmunizations in a significant percentage of
blood transfusion recipients requires assessment of blood group systems beyond
ABO and RhD. Of these, the Kell, Kidd, and Duffy systems are the most
clinically significant," explained Dr. Christoph Gassner, the lead researcher
on the study published in Transfusion and the Head of Research and Development
at the Swiss Red Cross' Blood Transfusion Service in Zurich, Switzerland.

"Our study conclusively shows that the MassARRAY System and our genotyping
assay designs can correctly predict the Kell, Kidd, and Duffy blood groups for
greater than 99% of all Swiss blood donors. The MassARRAY System's open format
even enabled us to discover some new silencing alleles found in less than 1%
of our study population," said Gassner. "The technology holds great potential
for precision genotyping of frequent donors' blood groups to ensure safe blood
transfusions, particularly for recipients requiring continual transfusions."

"The Blood Transfusion Service, Zurich and Agena Bioscience will continue to
deepen this already productive collaboration by expanding our validation
studies to other blood group systems, including the MNS system and other blood
diseases," said Dr. Beat Frey, Director of Hematology and Laboratory Medicine
at the Swiss Red Cross' Blood Transfusion Service in Zurich.

Agena Bioscience's new research use only Hemo ID Blood Group Genotyping Panel
is a DNA-based antigen typing technology for erythrocytes, platelets, and
neutrophils. The panel generates predicted phenotypes for 23 platelet and
neutrophil antigens as well as 101 antigens in 16 blood group systems
(Kell-Kidd-Duffy, MNS, Rare Blood Groups, RHD- RHCE Broad, RHD Variant, and
HPA & HNA). A unique RHD Broad module enables assignment of zero, one or two
copies of RHD.

In 2013, the Swiss Red Cross scientists published in Transfusion Medicine
Reviews its first study assessing the MassARRAY system's reliability and
sensitivity for blood group genotyping a wide range of blood groups, including
many rhesus variants.

"The modular design of the Hemo ID Blood Group Genotyping Panel allows
researchers to either run the comprehensive panel or to select from the six
Hemo ID sub-panels. This flexibility enables the researchers to focus on the
content of their interest and save both cost and time," said John Lillig, the
Chairman and interim CEO of Agena Bioscience. "The Hemo ID Panel is an
important addition to our applications portfolio in a market segment that is
primed to adopt DNA-based blood group typing as a powerful complement to
traditional serotyping."

The Hemo ID panel utilizes the MassARRAY Analyzer 4 MALDI-TOF mass
spectrometer and the iPLEX^® Pro chemistry for end-point PCR and single
nucleotide extension and termination reactions. A modular format allows
comprehensive or focused analyses of up to 3000 genomic DNA samples in eight
hours.

For more information on the Hemo ID Blood Group Genotyping Panel, visit
http://www.agenabioscience.com/HemoID.

About Agena Bioscience
Agena Bioscience is a San Diego, CA based life sciences and clinical
diagnostics company that recently acquired the Bioscience business of
Sequenom, Inc. and is now offering the MassARRAY® System. The system is a
highly sensitive, quantitative method for nucleic acid detection via MALDI-TOF
mass spectrometry for high-throughput genotyping and mutation profiling for
cancer and other disease research, companion diagnostics, pharmacogenomics,
epigenetics, clinical genetics, ag-bio genetics, and biobanking molecular
sample identification.
www.agenabioscience.com

Logo- http://photos.prnewswire.com/prnh/20140530/92768

SOURCE Agena Bioscience

Website: http://www.agenabioscience.com
Contact: Ryan Ferrell, Desk/Mobile: 312.506.5202, ryan.ferrell@hdmz.com
 
Press spacebar to pause and continue. Press esc to stop.